Blogs about: Series D
Featured Blog
PeptImmune, Inc.: Series D $8.2M
PeptImmune Inc. (Cambridge, MA) a clinical stage biotechnology company utilizing novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders such … more →
OnBioVC
PeptImmune, Inc.: Series D $8.2M
arubenstein wrote 1 year ago: PeptImmune Inc. (Cambridge, MA) a clinical stage biotechnology company utilizing novel and proven te … more →
ChemoCentryx, Inc.: Series D $29.9M
arubenstein wrote 2 years ago: ChemoCentryx (Mountain View, CA) a developer of drugs for autoimmune diseases, inflammatory diseases … more →
